For decades, the medical establishment has poured billions of dollars into finding a cure—or even a meaningful treatment—for Alzheimer’s disease and related dementias. The results have been largely disappointing. But a growing body of research is now pointing toward an unexpected and remarkably accessible intervention: the shingles vaccine. Multiple studies, drawing on vast population-level data from several countries, suggest that vaccination against herpes zoster may reduce the risk of dementia by a significant margin, raising profound questions about the underlying causes of neurodegeneration and the future of preventive medicine.
The latest evidence, as reported by Ars Technica, continues to strengthen the case. What began as an intriguing epidemiological observation has evolved into a serious scientific hypothesis backed by data from millions of patients across the United States, the United Kingdom, and Scandinavia. The signal is consistent, the effect sizes are meaningful, and the biological plausibility is increasingly well-supported.
From Correlation to Conviction: The Evidence Builds
The story begins with the varicella-zoster virus (VZV), the pathogen responsible for chickenpox in childhood and shingles in older adults. After a primary chickenpox infection, VZV lies dormant in nerve cells for decades. When the immune system weakens with age, the virus can reactivate, causing the painful blistering rash known as shingles. But researchers have long suspected that VZV reactivation may also cause damage in the brain, potentially triggering or accelerating neurodegenerative processes.
The first major clue came from studies in Taiwan and other countries that found people who had experienced shingles had a modestly elevated risk of developing dementia in subsequent years. But correlation is not causation, and the medical community remained cautious. Then came a wave of studies examining whether vaccination against shingles—which suppresses VZV reactivation—might correspondingly reduce dementia risk. The results have been striking.
Natural Experiments and the Power of Policy Changes
One of the most compelling study designs has exploited natural experiments created by government vaccination policies. In Wales, for example, the shingles vaccine was introduced in 2013 with a strict age-based eligibility cutoff: people born on or after September 2, 1933, were eligible for the vaccine, while those born just one day earlier were not. This arbitrary cutoff created a near-perfect natural experiment, allowing researchers to compare dementia rates between two groups that were virtually identical in every respect except their access to the vaccine.
A landmark 2023 study by Stanford economist Paul Romer’s former student, economist Markus Eyting, and colleagues, published in the journal Nature Medicine, used this Welsh policy discontinuity to estimate the causal effect of shingles vaccination on dementia. The findings were remarkable: vaccination was associated with a reduction in new dementia diagnoses of roughly 20% over a seven-year follow-up period. The study controlled for a wide range of confounders and used rigorous regression discontinuity methods, making it one of the strongest pieces of evidence to date.
Replication Across Borders and Datasets
What makes the shingles-dementia connection particularly persuasive is that it has been replicated independently in multiple countries using different datasets and methodologies. Researchers in the United States have used Medicare claims data covering tens of millions of older Americans to examine the relationship, and they have found similar protective associations. Studies from Scandinavian countries, which maintain comprehensive national health registries, have added further confirmation.
According to Ars Technica, newer analyses have continued to reinforce the original findings, with some researchers reporting that the protective effect may be even larger than initially estimated. The consistency of the signal across different populations, health systems, and analytic approaches has moved many scientists from skepticism to serious engagement with the hypothesis.
The Biological Mechanism: Viruses and the Aging Brain
The epidemiological data would mean little without a plausible biological mechanism. Fortunately, laboratory research has been filling in the gaps. VZV is a herpesvirus, and herpesviruses are known for their ability to establish lifelong latent infections in the nervous system. When VZV reactivates, it travels along nerve fibers, causing inflammation and tissue damage. In some cases, this reactivation can affect cranial nerves and even brain tissue directly.
Moreover, there is a growing body of evidence linking another herpesvirus—herpes simplex virus type 1 (HSV-1), which causes cold sores—to Alzheimer’s disease. Researchers including Ruth Itzhaki of the University of Manchester have spent decades documenting the presence of HSV-1 in the brains of Alzheimer’s patients and showing that the virus can trigger the formation of amyloid-beta plaques, the hallmark pathological feature of the disease. VZV may act through similar or complementary pathways, either by directly damaging neurons, by triggering chronic neuroinflammation, or by reactivating latent HSV-1 in the brain.
A 2024 Study Adds Another Layer
Research published in 2024 by a team at Tufts University provided direct laboratory evidence that VZV infection of neural cells can reactivate dormant HSV-1, leading to the production of amyloid-beta and phosphorylated tau—both key markers of Alzheimer’s pathology. This finding offered a mechanistic bridge between shingles virus reactivation and the molecular hallmarks of dementia, giving the epidemiological associations a concrete biological foundation.
The implication is that the shingles vaccine may not simply prevent a painful rash; it may prevent a cascade of viral reactivation events in the brain that contribute to neurodegeneration over years or decades. If this hypothesis is correct, it would represent one of the most significant advances in dementia prevention in the history of the field—achieved not through a novel drug, but through a vaccine that already exists and is widely available.
The Recombinant Vaccine May Be More Effective
An important nuance in the research involves the type of shingles vaccine used. The older live-attenuated vaccine, Zostavax, was the product studied in many of the initial analyses, including the Welsh natural experiment. However, Zostavax has been largely replaced by Shingrix, a recombinant adjuvanted vaccine manufactured by GlaxoSmithKline that is significantly more effective at preventing shingles. Shingrix was approved in the United States in 2017 and has since become the standard of care.
Some researchers have speculated that if the live vaccine showed a 20% reduction in dementia risk, the more potent Shingrix could potentially offer an even greater protective effect. However, because Shingrix is newer, long-term follow-up data on dementia outcomes are still being collected. Early observational data from U.S. Medicare populations, as noted by Ars Technica, suggest that Shingrix may indeed provide stronger protection, though definitive conclusions will require more time and larger studies.
Why Randomized Trials Are Both Needed and Difficult
Despite the accumulating evidence, many in the medical community are calling for randomized controlled trials—the gold standard of clinical research—before making definitive claims about the vaccine’s neuroprotective effects. The challenge is that such trials would be enormously expensive and logistically complex. Dementia develops over many years, meaning a trial would need to follow participants for a decade or more. Additionally, because the shingles vaccine is already recommended for older adults on its own merits, it would be ethically problematic to withhold it from a control group.
Some creative solutions have been proposed. Researchers could conduct trials in populations where the vaccine has not yet been widely adopted, or they could use adaptive trial designs that incorporate interim analyses. There has also been discussion of piggybacking dementia endpoints onto existing vaccine studies or health system databases. The National Institutes of Health and other funding bodies are reportedly considering how best to support such research.
Implications for Public Health and the Dementia Crisis
The potential public health implications are enormous. Alzheimer’s disease and related dementias affect more than 55 million people worldwide, a number projected to nearly triple by 2050 as populations age. Current treatments, including the recently approved anti-amyloid antibodies lecanemab and donanemab, offer only modest benefits and come with significant side effects and costs. A preventive vaccine that is already approved, widely available, and covered by insurance would be transformative.
Even a 20% reduction in dementia incidence, if confirmed, would translate into millions of cases prevented globally, along with enormous savings in healthcare costs and caregiver burden. The shingles vaccine costs a fraction of what new dementia drugs cost, and it is already part of routine immunization schedules for adults over 50 in many countries. If the neuroprotective effect is real, the public health case for expanding vaccination coverage becomes even more compelling.
What Comes Next for Researchers and Clinicians
The scientific community is now at an inflection point. The observational evidence is strong and growing stronger. The biological mechanisms are plausible and increasingly well-characterized. What remains is the hard work of designing and funding definitive trials, refining our understanding of which populations benefit most, and determining whether the effect extends to specific types of dementia or is more general.
For clinicians and patients, the practical message is straightforward: the shingles vaccine is already recommended for adults over 50, and the evidence for its benefits—including the potential neuroprotective effect—continues to mount. While no one is yet ready to market Shingrix as a dementia vaccine, the data suggest that getting vaccinated may offer benefits that extend well beyond preventing a painful rash. In a field that has seen far too many disappointments, the shingles-dementia connection stands out as a rare and genuinely hopeful development.